AR121363A1 - COMPOSITIONS AND USES OF GLP-1 - Google Patents

COMPOSITIONS AND USES OF GLP-1

Info

Publication number
AR121363A1
AR121363A1 ARP210100417A ARP210100417A AR121363A1 AR 121363 A1 AR121363 A1 AR 121363A1 AR P210100417 A ARP210100417 A AR P210100417A AR P210100417 A ARP210100417 A AR P210100417A AR 121363 A1 AR121363 A1 AR 121363A1
Authority
AR
Argentina
Prior art keywords
compositions
glp
semaglutide
kits
peptide
Prior art date
Application number
ARP210100417A
Other languages
Spanish (es)
Inventor
Dorthe Engelund Kot
Sren Snitker
Andrew Mark Louw
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR121363A1 publication Critical patent/AR121363A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a las composiciones farmacéuticas del péptido GLP-1 semaglutida que comprende no más de 0,1% (p/p) de fenol y más de 6,4 mg/ml de cloruro de sodio, su preparación, kits que comprenden dichas composiciones, así como también sus usos.The present refers to the pharmaceutical compositions of the GLP-1 semaglutide peptide that comprises no more than 0.1% (w/w) of phenol and more than 6.4 mg/ml of sodium chloride, its preparation, kits that comprise said compositions, as well as their uses.

ARP210100417A 2020-02-18 2021-02-18 COMPOSITIONS AND USES OF GLP-1 AR121363A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20157963 2020-02-18

Publications (1)

Publication Number Publication Date
AR121363A1 true AR121363A1 (en) 2022-06-01

Family

ID=69699784

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP210100418A AR121364A1 (en) 2020-02-18 2021-02-18 PHARMACEUTICAL FORMULATIONS
ARP210100417A AR121363A1 (en) 2020-02-18 2021-02-18 COMPOSITIONS AND USES OF GLP-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP210100418A AR121364A1 (en) 2020-02-18 2021-02-18 PHARMACEUTICAL FORMULATIONS

Country Status (1)

Country Link
AR (2) AR121364A1 (en)

Also Published As

Publication number Publication date
AR121364A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
CO2022011728A2 (en) Compositions and uses of glp-1
CL2021001430A1 (en) Glp-1 compositions and their uses. (request divisional 202000422)
CL2022003510A1 (en) Cysteine protease inhibitors and their methods of use
CO2022018811A2 (en) Kras g12c protein inhibitors and their uses
ECSP22076862A (en) ANTIVIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF
MX2022016405A (en) 1'-cyano nucleoside analogs and uses thereof.
CO2022010330A2 (en) Gamma-Hydroxybutyrate (GHB) Dosage
CL2019002190A1 (en) Reduction of the viscosity of pharmaceutical formulations that comprise a therapeutic protein at a concentration of at least 70 mg / ml, where the therapeutic protein is not an antibody (divisional application 201700984)
CO2019007409A2 (en) Tricyclic enone pyrimidin derivatives for rorγ inhibition and other uses
CO2021005915A2 (en) Stable compositions of semaglutide and uses thereof
UY38228A (en) TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CO2022012884A2 (en) Fused Amino Pyrimidine Compounds
CO2022014499A2 (en) nlrp3 modulators
BR112020004935A8 (en) A PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY THAT SPECIFICALLY BINDS TO THE N-TERMINAL OF LYSYL-TRNA SYNTHASE AS AN ACTIVE PRINCIPLE FOR THE PREVENTION OR TREATMENT OF DISEASE RELATED TO CELL MIGRATION
AR087371A1 (en) FORMULATIONS OF (TRIMETOXIFENILAMINO) PYRIMIDINYL, METHODS
AR121363A1 (en) COMPOSITIONS AND USES OF GLP-1
BR112022003046A8 (en) Il-15 conjugate, its method of preparation and its uses, as well as pharmaceutical composition and in vitro method of expanding one or more of the t cell populations
CL2023001747A1 (en) Pharmaceutical composition of dual glp-1/glp-2 agonists
CL2023001745A1 (en) Pharmaceutical composition of dual glp-1/glp-2 agonists
UY38426A (en) USE OF LOW VOLUME PLASMA REPLACEMENT FOR THE TREATMENT OF ALZHEIMER'S DISEASE IN EARLY AND MODERATE STAGES
AR103719A1 (en) TOPICAL LIQUID COMPOSITION FOR INTRAUTERINE WASHING CONTAINING MELATONIN
UY38473A (en) PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION
AR117097A1 (en) PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION
BR112022006313A2 (en) PEDIATRIC SUSPENSION FORMULATION
CO2021016391A1 (en) Antiviral liquid pharmaceutical composition against sars-cov-2